Developing the COVID-19 vaccine is only half the battle
Distributing a safe and effective COVID-19 vaccine may be even more challenging than developing it, which is why CU 91أغجز¸َ researchers and the CU spinoff are so focused on finding a way to get vaccines to 7.8 billion people.
The researchers are focused on a vaccine-manufacturing platform technology that addresses the need for temperature-stable, single-dose formulations of novel COVID-19 vaccines at the scale required for large human clinical trials.
The research team is able to do so with funding, licensing and startup support from Venture Partners at CU 91أغجز¸َ, the university’s commercialization arm. They also received a grant from the Boettcher Foundation, which has awarded nearly $1 million to help combat the COVID-19 pandemic.
“It has to be a solution that is suitable for the entire world,†said project lead Theodore Randolph, Gillespie Professor in the Department of Chemical and Biological Engineering.
Theodore Randolph removes vaccines.